MARGARET A. FISCHL, M.D.; GORDON M. DICKINSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Pneumocystis carinii pneumonia is a major cause of morbidity and mortality in patients with the acquired immunodeficiency syndrome (AIDS). More than 50% of patients with AIDS develop P. carinii pneumonia, and despite therapy more than 16% die with overwhelming infection. Several studies have shown that the combination of trimethoprim-sulfamethoxazole is effective in the treatment and prevention of P. carinii infection (1, 2). However, its use in patients with AIDS has been associated with a high incidence of adverse reactions (3). The report of Hardy and colleagues (4) that Fansidar (sulfadoxine-pyrimethamine; Hoffmann-LaRoche Inc., Nutley, New Jersey) taken once
FISCHL MA, DICKINSON GM. Fansidar Prophylaxis of Pneumocystis Pneumonia in the Acquired Immunodeficiency Syndrome. Ann Intern Med. ;105:629. doi: 10.7326/0003-4819-105-4-629_1
Download citation file:
Published: Ann Intern Med. 1986;105(4):629.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use